Spero’s stock slides after antibiotic flops in Phase II trial

Spero’s stock slides after antibiotic flops in Phase II trial

Submitted by admin on October 30, 2024 - 11:44am
Source: 
Clinical Trials Arena
News Tags: 
Spero Therapeutics
SPR720
non-tuberculous mycobacteria pulmonary disease
clinical trials
Headline: 
Spero’s stock slides after antibiotic flops in Phase II trial
snippet: 

The company has also laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial pulmonary disease (NTM-PD).

Do Not Allow Advertisers to Use My Personal information